GB Sciences is a preclinical-stage biopharmaceutical company developing patented, plant-inspired drug formulations for the prescription drug market. The company's core concept is what it calls "minimum essential mixtures" (MEMs) — precisely defined combinations of cannabinoids, terpenes, and other plant-derived compounds designed to treat specific diseases more effectively than either single-ingredient drugs or whole-plant extracts. GB Sciences has no commercial products or drug revenue; its value lies almost entirely in its IP portfolio and its pipeline of preclinical drug candidates. Lead programs target Parkinson's disease motor symptoms, chronic pain, anxiety/depression, cytokine release syndrome, and cardiovascular disease — all preclinical. A central asset is its PhAROS platform, an AI-enabled drug discovery tool that analyzes traditional medical systems worldwide and uses machine learning to identify novel MEMs, which GB Sciences claims has shortened discovery-to-patent timelines from roughly seven years to about 1.5 years. The company operates as a lean, two-employee "virtual" R&D operation, outsourcing all lab and animal studies to university partners and CROs. GB Sciences' business model is to discover, patent, and develop these formulations, then out-license them to larger pharma companies in exchange for licensing fees, milestones, and royalties. GB Sciences is also exploring separately licensing the PhAROS platform. The company depends on external capital or partnership funding to advance any program into clinical trials.